US6642268B2
(en)
|
1994-09-13 |
2003-11-04 |
G.D. Searle & Co. |
Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
|
US6262277B1
(en)
|
1994-09-13 |
2001-07-17 |
G.D. Searle And Company |
Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
|
WO2000035889A1
(en)
*
|
1998-12-11 |
2000-06-22 |
Sankyo Company, Limited |
Substituted benzylamines
|
ATE242007T1
(en)
|
1998-12-23 |
2003-06-15 |
Searle Llc |
COMBINATIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND NICOTINIC ACID DERIVATIVES FOR CARDIOVASCULAR INDICATIONS
|
TR200002099A2
(en)
*
|
1999-07-22 |
2001-06-21 |
Sankyo Company Limited |
Cyclobutene derivatives, their preparation and therapeutic uses
|
YU19302A
(en)
*
|
1999-09-22 |
2004-11-25 |
Aventis Pharma Deutschland Gmbh. |
4-benzylaminoquinoline conjugates with bile acid and their heteroanalogues, methods for producing the same, medicaments containing these compounds and their use
|
MXPA04006255A
(en)
|
2002-01-17 |
2004-09-27 |
Pharmacia Corp |
Novel alkyl/aryl hydroxy or keto thiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (asbt) and taurocholate uptake.
|
GB0307918D0
(en)
|
2003-04-05 |
2003-05-14 |
Astrazeneca Ab |
Therapeutic use
|
US7977359B2
(en)
|
2005-11-04 |
2011-07-12 |
Amira Pharmaceuticals, Inc. |
5-lipdxygenase-activating protein (FLAP) inhibitors
|
US8399666B2
(en)
|
2005-11-04 |
2013-03-19 |
Panmira Pharmaceuticals, Llc |
5-lipoxygenase-activating protein (FLAP) inhibitors
|
GB2431927B
(en)
|
2005-11-04 |
2010-03-17 |
Amira Pharmaceuticals Inc |
5-Lipoxygenase-activating protein (FLAP) inhibitors
|
CA2669704A1
(en)
*
|
2006-11-16 |
2008-05-22 |
Allergan, Inc. |
Sulfoximines as kinase inhibitors
|
CN102083797B
(en)
|
2008-04-01 |
2014-06-04 |
Abbvie公司 |
Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy
|
CN102137858B
(en)
|
2008-05-23 |
2014-07-23 |
潘米拉制药有限责任公司 |
5-lipoxygenase-activating protein inhibitor
|
AR075442A1
(en)
|
2009-02-16 |
2011-03-30 |
Abbott Gmbh & Co Kg |
AMINOTETRALINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USES IN THERAPY
|
EP2995317A1
(en)
|
2010-05-26 |
2016-03-16 |
Satiogen Pharmaceuticals, Inc. |
Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
|
US9051280B2
(en)
|
2010-08-13 |
2015-06-09 |
AbbVie Deutschland GmbH & Co. KG |
Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
|
US8877794B2
(en)
|
2010-08-13 |
2014-11-04 |
Abbott Laboratories |
Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
|
US8846743B2
(en)
|
2010-08-13 |
2014-09-30 |
Abbott Laboratories |
Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
|
US9045459B2
(en)
|
2010-08-13 |
2015-06-02 |
AbbVie Deutschland GmbH & Co. KG |
Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
|
US8883839B2
(en)
|
2010-08-13 |
2014-11-11 |
Abbott Laboratories |
Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
|
EP3400944B1
(en)
|
2010-11-04 |
2020-07-15 |
Albireo AB |
Ibat inhibitors for the treatment of liver diseases
|
US9309200B2
(en)
|
2011-05-12 |
2016-04-12 |
AbbVie Deutschland GmbH & Co. KG |
Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
|
TW201319049A
(en)
|
2011-08-05 |
2013-05-16 |
Abbott Gmbh & Co Kg |
Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
|
SG10201909122QA
(en)
|
2011-10-28 |
2019-11-28 |
Lumena Pharmaceuticals Inc |
Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
|
US20130108573A1
(en)
|
2011-10-28 |
2013-05-02 |
Lumena Pharmaceuticals, Inc. |
Bile Acid Recycling Inhibitors for Treatment of Hypercholemia and Cholestatic Liver Disease
|
US8846741B2
(en)
|
2011-11-18 |
2014-09-30 |
Abbvie Inc. |
N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
|
US9365512B2
(en)
|
2012-02-13 |
2016-06-14 |
AbbVie Deutschland GmbH & Co. KG |
Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
|
US9656955B2
(en)
|
2013-03-15 |
2017-05-23 |
Abbvie Inc. |
Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
|
AU2014229050A1
(en)
|
2013-03-15 |
2015-10-22 |
Lumena Pharmaceuticals Llc |
Bile acid recycling inhibitors for treatment of Barrett's esophagus and gastroesophageal reflux disease
|
US9650334B2
(en)
|
2013-03-15 |
2017-05-16 |
Abbvie Inc. |
Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
|
BR112015023646A2
(en)
|
2013-03-15 |
2017-07-18 |
Lumena Pharmaceuticals Inc |
Recycling bile acid inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
|
AU2014336154A1
(en)
|
2013-10-17 |
2016-04-28 |
AbbVie Deutschland GmbH & Co. KG |
Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
|
EP3057960B1
(en)
|
2013-10-17 |
2019-02-27 |
AbbVie Deutschland GmbH & Co. KG |
Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
|
US10709755B2
(en)
|
2014-06-25 |
2020-07-14 |
Elobix Ab |
Solid formulation and method for preventing or reducing coloration thereof
|
US10441604B2
(en)
|
2016-02-09 |
2019-10-15 |
Albireo Ab |
Cholestyramine pellets and methods for preparation thereof
|
US10441605B2
(en)
|
2016-02-09 |
2019-10-15 |
Albireo Ab |
Oral cholestyramine formulation and use thereof
|
US10786529B2
(en)
|
2016-02-09 |
2020-09-29 |
Albireo Ab |
Oral cholestyramine formulation and use thereof
|
EP3664781A1
(en)
|
2017-08-09 |
2020-06-17 |
Albireo AB |
Cholestyramine granules, oral cholestyramine formulations and use thereof
|
US10793534B2
(en)
|
2018-06-05 |
2020-10-06 |
Albireo Ab |
Benzothia(di)azepine compounds and their use as bile acid modulators
|
WO2019234077A1
(en)
|
2018-06-05 |
2019-12-12 |
Albireo Ab |
Benzothia(di)azepine compounds and their use as bile acid modulators
|
BR112020024461A2
(en)
|
2018-06-20 |
2021-03-23 |
Albireo Ab |
pharmaceutical formulation of odevixibat, process for the preparation of the pharmaceutical formulation, and, formulation.
|
US11801226B2
(en)
|
2018-06-20 |
2023-10-31 |
Albireo Ab |
Pharmaceutical formulation of odevixibat
|
US11007142B2
(en)
|
2018-08-09 |
2021-05-18 |
Albireo Ab |
Oral cholestyramine formulation and use thereof
|
US10722457B2
(en)
|
2018-08-09 |
2020-07-28 |
Albireo Ab |
Oral cholestyramine formulation and use thereof
|
US11549878B2
(en)
|
2018-08-09 |
2023-01-10 |
Albireo Ab |
In vitro method for determining the adsorbing capacity of an insoluble adsorbant
|
US10975045B2
(en)
|
2019-02-06 |
2021-04-13 |
Aibireo AB |
Benzothiazepine compounds and their use as bile acid modulators
|
FI3921028T3
(en)
|
2019-02-06 |
2023-01-31 |
|
Benzothiadiazepine compounds and their use as bile acid modulators
|
US10941127B2
(en)
|
2019-02-06 |
2021-03-09 |
Albireo Ab |
Benzothiadiazepine compounds and their use as bile acid modulators
|
DK3923943T3
(en)
|
2019-02-12 |
2024-08-26 |
Mirum Pharmaceuticals Inc |
Genotype and dose-dependent response to an ASBTI in patients with bile salt export pump deficiency
|
CN114341100A
(en)
|
2019-08-28 |
2022-04-12 |
联合利华知识产权控股有限公司 |
Novel compounds for skin lightening
|
CN114375291B
(en)
|
2019-08-28 |
2024-03-08 |
联合利华知识产权控股有限公司 |
Novel compounds for skin lightening
|
CA3158181A1
(en)
|
2019-12-04 |
2021-06-10 |
Albireo Ab |
Benzothia(di)azepine compounds and their use as bile acid modulators
|
JP2023504647A
(en)
|
2019-12-04 |
2023-02-06 |
アルビレオ・アクチボラグ |
Benzothia(di)azepine compounds and their use as bile acid modulators
|
US11014898B1
(en)
|
2020-12-04 |
2021-05-25 |
Albireo Ab |
Benzothiazepine compounds and their use as bile acid modulators
|
PE20230234A1
(en)
|
2019-12-04 |
2023-02-07 |
Albireo Ab |
BENZOTI(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS
|
CN114761018A
(en)
|
2019-12-04 |
2022-07-15 |
阿尔比里奥公司 |
Benzothiadiazepine compounds and their use as bile acid modulators
|
CN116157389A
(en)
|
2020-08-03 |
2023-05-23 |
阿尔比里奥公司 |
Benzothiazepine compounds and their use as bile acid modulators
|
KR20230106651A
(en)
|
2020-11-12 |
2023-07-13 |
알비레오 에이비 |
Odevixivat for the treatment of progressive familial intrahepatic cholestasis (PFIC)
|
CN116583504A
(en)
|
2020-12-04 |
2023-08-11 |
阿尔比里奥公司 |
Benzothiazepine compounds and their use as bile acid modulators
|